Utilisation of Angiox® in European Practice

The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stable Angina (SA) Angina Pectoris Angina, Stable Cardiovascular Diseases Chest Pain Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia NSTE-ACS (NSTEMI and UA) Necrosis Neurologic Manifestations Non-ST Elevated Myocardial Infarction Pain Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction STEMI (STE-ACS) Signs and Symptoms Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Universitaire de Caen, Caen, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Eligible for, and receive treatment with Angiox®.
Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations

Exclusion criteria

Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment.
Patients not eligible for treatment for Angiox®.

Treatment and study plan

Primary outcomes

Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered

Time frame: from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier).

Secondary outcomes

Death Myocardial infarction Unplanned revascularisation Stroke Major* and minor bleeding Thrombocytopenia Stent thrombosis Adverse events and serious adverse events

Time frame: measured in-hospital (prior to discharge), and at post-hospital discharge in outpatient as per local practice (30 days)

Sponsors and collaborators

Lead sponsor

The Medicines Company

Industry

Registry information

Official study title

A Registry Study to Determine Utilisation Patterns in Patients Receiving Angiox®, and Collect Descriptive Safety and Outcome Data to Inform the Risk Management Strategy for Europe.

Acronym: EURO-vision

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Nov 11, 2009
Registry last updated: Jan 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting